What side effects are associated with this type of intervention?

Narrative, technology-based, and recovery-oriented interventions like THRIVE generally have minimal physical side effects compared to pharmacological treatments. However, patients may experience emotional discomfort as they confront and process distressing thoughts and feelings. Additionally, technology-based interventions may pose challenges such as digital fatigue, privacy concerns, and the need for reliable internet access. Overall, these interventions are considered safe and are designed to support mental health recovery by providing meaningful engagement and reducing suicidal ideation.

What prior FDA approvals exist?

The FDA has approved several pharmacological treatments for reducing suicidal ideation, including esketamine (Spravato) for treatment-resistant depression, which has shown rapid reduction in suicidal thoughts. However, there are limited FDA-approved non-pharmacological treatments specifically for suicide prevention. The THRIVE intervention, which is narrative, technology-based, and recovery-oriented, represents a novel approach that is not yet widely reflected in FDA-approved treatments. Current non-pharmacological strategies often include cognitive-behavioral therapy (CBT) and dialectical behavior therapy (DBT), which focus on reducing suicidal ideation and improving coping mechanisms.

What other types of research exist?

Promising alternatives to THRIVE for suicide patients include: 1) Internet-based guided self-help CBT, which has shown efficacy in reducing binge eating and could be adapted for suicide prevention. 2) Smartphone applications like Noom Monitor, which support self-monitoring and behavioral change. 3) Collaborative care models that integrate psychopharmacology and psychotherapy, enhancing patient-centered care and adherence. 4) Digital CBT-I, which has demonstrated improvements in psychological well-being and could be tailored for suicide prevention. These interventions leverage technology to provide accessible, supportive, and effective care for individuals at risk of suicide.

← Back to Search

THRIVE Intervention for Suicide Crisis (THRIVE Trial)

N/A

Waitlist Available

Led By Jennifer Lockman, PhD

Research Sponsored by Centerstone Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests THRIVE, a session using a tablet to help suicidal individuals at Crisis Stabilization Centers. It involves talking about their crisis, understanding it better, and setting future goals to increase hope and self-confidence. The goal is to provide more effective care than typical emergency departments. Thrive has been shown to be effective in reducing depression and anxiety symptom severity and improving functioning and resilience among a mostly rural community population of US adults.

Who is the study for?

This trial is for English-speaking residents of Davidson County who are at increased risk for suicide and have been admitted to a Crisis Stabilization Center. Participants must be able to give informed consent, provide contact information for follow-ups, and discuss their suicidal thoughts or attempts. Those acutely psychotic or unable to communicate with the research team cannot join.

What is being tested?

The study tests THRIVE, a new 60-minute recovery-oriented intervention using narrative and technology, against usual care in Crisis Stabilization Centers. It aims to see if THRIVE can better help individuals understand their suicide crisis, reduce suicidal thoughts, and support recovery.

What are the potential side effects?

Since THRIVE is a psychological intervention rather than a medication, it may not have typical 'side effects' but could potentially cause emotional discomfort when discussing sensitive topics like suicide.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hopefulness

Meaning made of stress

Self-efficacy to avoid suicidal action

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Experimental: THRIVE + Usual CareExperimental Treatment2 Interventions

Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk

Group II: Usual CareActive Control1 Intervention

Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

THRIVE

2017

N/A

~560

Usual Care

1990

Completed Phase 4

~7700

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for suicide, particularly those similar to the THRIVE intervention, include narrative, technology-based, and recovery-oriented approaches. These treatments help patients make sense of their suicidal crises, reduce suicidal ideation, and promote recovery. The narrative component allows patients to articulate their experiences, fostering understanding and control. Technology-based interventions provide accessible support, crucial for immediate crisis management. Recovery-oriented approaches emphasize personal growth and resilience, encouraging coping strategies and meaningful life goals. These mechanisms address emotional and cognitive factors, provide ongoing support, and empower patients to rebuild their lives.

A treatment strategy for meeting life as it is. Patients' and therapists' experiences of brief therapy in a district psychiatric centre: A qualitative study.Use of a Fully Automated Internet-Based Cognitive Behavior Therapy Intervention in a Community Population of Adults With Depression Symptoms: Randomized Controlled Trial.